Year All20262025202420232022202120202019 October 16, 2025 atai Life Sciences Announces Proposed Public Offering of Common Shares October 16, 2025 atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression September 23, 2025 atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression September 18, 2025 atai Life Sciences Awarded Grant from the National Institutes of Health August 28, 2025 atai Life Sciences to Participate in September Investor Conferences August 14, 2025 atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates July 25, 2025 Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia July 1, 2025 atai Life Sciences Announces $50 Million Private Placement Financing July 1, 2025 atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression June 2, 2025 atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
October 16, 2025 atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
September 23, 2025 atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
August 14, 2025 atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
July 25, 2025 Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
July 1, 2025 atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
June 2, 2025 atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
